Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ovarian Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    727 result(s) found for: Ovarian Cancer. Displaying page 1 of 37.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004484-54 Sponsor Protocol Number: IP-CAT-OC-02 Start Date*: 2007-08-30
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
    Medical condition: Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    9.1 10033161 Ovarian epithelial cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001661-32 Sponsor Protocol Number: VeTo Start Date*: 2012-07-05
    Sponsor Name:Vejle Hospital, Dept. of Oncology
    Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
    Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001506-25 Sponsor Protocol Number: NN028-1802 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Stand...
    Medical condition: advanced epithelial Ovarian Cancer stage IIB-IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002014-22 Sponsor Protocol Number: ONK-MAP/AZD2281-01 Start Date*: 2014-05-27
    Sponsor Name:Országos Onkológiai Intézet
    Full Title: An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer
    Medical condition: advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001724-40 Sponsor Protocol Number: MITO-6 Start Date*: 2005-10-18
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
    Full Title: Phase II study with capecitabine as monotherapy in the treatment of platinum resistant or refractory ovarian cancer
    Medical condition: Cytologic or histologic diagnosis of relapsed ovarian cancer, refractory or resistant to platinum salts.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061328 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023457-11 Sponsor Protocol Number: S52798 Start Date*: 2011-02-15
    Sponsor Name:UZ Leuven
    Full Title: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer
    Medical condition: advanced/recurrent ovarian and endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057529 Ovarian cancer metastatic LLT
    12.1 10066697 Ovarian cancer recurrent LLT
    12.1 10057529 Ovarian cancer metastatic PT
    12.1 10066697 Ovarian cancer recurrent PT
    12.1 10014734 Endometrial cancer metastatic LLT
    12.1 10014736 Endometrial cancer recurrent LLT
    12.1 10014734 Endometrial cancer metastatic PT
    12.1 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005091-36 Sponsor Protocol Number: 2020-005091-36 Start Date*: 2021-08-30
    Sponsor Name:Stichting Catharina Hospital
    Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    Population Age: Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004429-41 Sponsor Protocol Number: BAY43-9006/12007 Start Date*: 2008-10-03
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ...
    Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033164 Ovarian epithelial cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033163 Ovarian epithelial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000366-36 Sponsor Protocol Number: TLK286.3025 Start Date*: 2006-06-07
    Sponsor Name:Telik, Inc.
    Full Title: Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory ...
    Medical condition: platinum refractory or resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033160 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003962-40 Sponsor Protocol Number: S043VELC02 Start Date*: 2006-03-22
    Sponsor Name:FONDAZIONE SENDO
    Full Title: An open label, Phase II study of biweekly VELCADETM and intermittent CAELIXTM in patients with ovarian cancer failing platinum containing regimens
    Medical condition: ovarian cancer failing platinum containing regimens
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061535 Ovarian neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023613-61 Sponsor Protocol Number: IPR/24 Start Date*: 2011-06-13
    Sponsor Name:MOLMED
    Full Title: NGR018: Randomized phase II study of NGR-hTNF plus pegylated liposomal doxorubicin (PLD) versus PLD in platinum-resistant ovarian cancer
    Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005725-64 Sponsor Protocol Number: CAGEM Start Date*: 2006-01-20
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
    Full Title: PHASE II CLINICAL AND PHARMACOKINETIC STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ADVANCED OVARIAN CARCINOMA
    Medical condition: OVARIAN ADENOCARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061328 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001224-35 Sponsor Protocol Number: TaxOvar Start Date*: 2012-08-13
    Sponsor Name:Vejle Hospital
    Full Title: Cabazitaxel in platinum refractory ovarian cancer. A phase II trial
    Medical condition: Platinum refractory ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007013-20 Sponsor Protocol Number: MK-0683-080 (P2135) Start Date*: 2007-02-23
    Sponsor Name:Onkologisk afdeling R and the Unit for Experimental Chemotherapy
    Full Title: A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer
    Medical condition: Advanced, recurrent epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033160 Ovarian epithelial cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023124-24 Sponsor Protocol Number: LUMCCHIP Start Date*: 2011-03-02
    Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum
    Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ...
    Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005674-31 Sponsor Protocol Number: HIPEC_ovaio Start Date*: 2007-10-30
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGICAL DEBULKING AND INTRAPERITONEAL CHEMOHYPERTHERMIA FOR STAGE III OVARIAN CANCER. A PROSPECTIVE PHASE II STUDY
    Medical condition: ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020030-25 Sponsor Protocol Number: APC-10E604 Start Date*: 2010-08-24
    Sponsor Name:ACCESS Pharmaceuticals, Inc
    Full Title: A Phase II Trial of ProLindac™ and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer
    Medical condition: Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017946-30 Sponsor Protocol Number: 20060517 Start Date*: 2011-01-19
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001755-45 Sponsor Protocol Number: OX4325 Start Date*: 2016-09-12
    Sponsor Name:Mateon Therapeutics, Inc.
    Full Title: FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bev...
    Medical condition: Platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002116-10 Sponsor Protocol Number: 40/2006/O/Sper Start Date*: 2006-05-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Carboplatin Gemcitabine as second line treatment in platinum sensitive advanced ovarian cancer phase II study on a new schedule.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA